Tempus AI rises after securing FDA approval for tumor test
29/05/2026 13:33
BUZZ-Tempus AI rises after securing FDA approval for tumor test ** Shares of AI-enabled precision medicine firm Tempus AI TEM.O rise 7.2% to $55.07 premarket
** Co says U.S. FDA approved its diagnostic tool, xT CDx, for genetic profiling of solid tumors to help doctors identify which therapies will work best for the patient
** The test is designed to detect genetic alterations without requiring a matching normal saliva or blood sample from the patient
** xT CDx is also approved as a companion diagnostic tool to identify colorectal cancer patients who may benefit from targeted therapies
** Up to last close, stock down 13.1% YTD
(Reporting by Christy Santhosh)